International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Oncol Lett 24: [Related article:] 434, 2022; DOI: 10.3892/ol.2022.13554
Following the publication of this article, the authors have realized that an incorrect description of the treatment protocol was reported in the “Postoperative procedures” subsection of the “Materials and methods” on p. 2 concerning the three regimens on which platinum-based chemoradiotherapy (CRT) was based. The sentence commencing on line 15 of this section should have read as follows (changes are highlighted in bold): “[Platinum-based concurrent CRT was performed based on one of three regimens: i) cisplatin (DDP) regimen-DDP [75 mg/m2 (not “45–50 mg/m2/day”)] on days 1–3; ii) DDP combined with 5-fluorouracil (5-FU) (PF regimen)-DDP [75 mg/m2 (not “40 mg/m2/day”)] on days 1–3 and 5-FU [650–700 mg/m2 (not 750–800 mg/m2/day)] on days 1–4 (not days 1–5); or iii) carboplatin (CBP) regimen-CBP (AUC=5) on days 1–2 [not, as was reported, “carboplatin (CBP)-based regimen-CBP, calcium folinate, and tegafur (200, 300, or 1,000 mg/m2/day, respectively) on days 1–3 for 1–2 cycles].
The authors regret that this misinformation was reported in the text, and thank the Editor of Oncology Letters for allowing them the opportunity to publish this Corrigendum.